At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in the Treatment of Seasonal Allergic Rhinitis (Study No. C94-145)
In Brief
A Phase 3 clinical trial evaluating Mometasone furoate nasal spray (MFNS), Loratadine, and 2 other interventions for Rhinitis, Allergic. Completed, enrolled 704 participants.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of mometasone furoate nasal spray (MFNS) with the addition of loratadine vs MFNS alone, loratadine alone, or placebo, in the treatment of patients with seasonal allergic rhinitis.
Study Details
Timeline
Interventions
Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
Daily dose of placebo administered as a nasal spray for 15 days.
Daily dose of placebo administered as an oral tablet for 15 days.